Page 2498 - Williams Hematology ( PDFDrive )

2469
2468 Index Index 2469

detection methods, 1711 consolidation therapy, 1752–1753 Myosin light-chain kinase, 1833t
DIS3, 233t, 1737 continuous therapy, 1753 Myristoylated alanine-rich C-kinase substrate
drug resistance and, 1711 cyclin-dependent kinase inhibitors, 218 (MARCKS), 667, 668f
early events, 1710 hematopoietic cell transplantation,
EGR1, 234t 364–366, 365f, 1750, 1755–1756 N
FAM46C, 1737 histone deacetylase inhibitors, 240, 1754 N -formyl FH , 584
5
4
FGFR3, 233t immunomodulatory drugs, 1754 N -methyl FH –homocysteine
5
4
heterogeneity, 1760 maintenance therapy, 1751–1752, 1752t methyltransferase, 585, 587f,
IGH, 188 monoclonal antibodies, 345, 345f, 346t, 589–590
5
KRAS (K-RAS), 188, 233t, 1709, 1737, 1754–1755 N -methyl FH –homocysteine
4
1759, 1760 of osteonecrosis of the jaw, 1757 methyltransferase deficiency, 608
late events, 1710–1711 of peripheral neuropathy, 1757 N370S, 1122, 1123, 1123t
LRRK2, 233t proteasome inhibitors, 342–343, N803, 487
MAF, 233t 1749–1750 NAD+, in glucose metabolism, 693
MYC, 1711 in relapsed or refractory disease, NADH, in glucose metabolism, 692
NRAS (N-RAS), 188, 233t, 1709, 1759 1753–1755, 1753t NADH diaphorase. See Cytochrome b 5
p53, 1710 response criteria, 1758, 1758t NADH-methemoglobin reductase, 692t
PRDM1, 234t in transplant-eligible patients, 1748t, NADP
prognosis and, 1759–1760 1750–1751 in folate metabolism, 584
RAS, 1710, 1735f, 1736t, 1737 in transplant-ineligible patients, 1751, in glucose metabolism, 694
RB/RB1, 234t, 1710 1752t NADPH
somatic, 1736–1737 of venous thromboembolism, in folate metabolism, 584, 585
TP53, 1735f 1756–1757 in glucose metabolism, 694
TP53, 233t, 1737 Myeloma stem cell, 1713–1714 in neurodegenerative disorders, 1840
marrow microenvironment, 1712–1713, Myelomastocytic leukemia (MML), 978 NADPH diaphorase, 692t, 701t, 790, 793
1737, 1738f Myelomonocytic leukemia. See Acute NADPH oxidase
myeloma stem cell, 1713–1714, 1734 myelomonocytic leukemia; in atherothrombosis, 2283
occupation, 1709, 1734 Chronic myelomonocytic leukemia in chronic granulomatous disease,
plasma cell differentiation, 1710, 1710f (CMML) 1027–1029, 1028f
preclinical models, 1739–1740, 1739f Myeloperoxidase (MPO), 107, 1011, 1012t, in inflammatory response, 286
radiation, 1709 1068f neutrophil granules and, 927
stages, 1734–1735, 1734f Myeloperoxidase (MPO) deficiency, 1020t, respiratory burst and, 1068f
Gaucher disease and, 1125 1033 Nadroparin, 2274t
IgM, 1760 Myelophthisic anemia, 657. See also Marrow, Nails, examination of, 8
initial evaluation, 1747, 1747t infiltration NAIT (neonatal alloimmune
laboratory features, 1740t Myeloproliferative disease, atypical, 1473 thrombocytopenia). See
blood, 1740–1741 Myeloproliferative leukemia virus (MPLV), Newborns/infants, alloimmune
imaging, 1715, 1748–1749, 1748f, 1749f 1822 thrombocytopenia in
immunoglobulins, 1714, 1741 Myelosuppression, for polycythemia vera, Nalidixic acid, maternal ingestion of, effect
lactate dehydrogenase levels, 1716 1298–1299, 1298t on fetus and newborn, 112, 112t
marrow, 31–32, 1715, 1741–1744, 1742f, MYH9 (Myh9), 1818, 1842 NAMPT (nicotinamide
1743f, 1744f MYH9-related thrombocytopenia phosphoribosyltransferase), 200
β -microglobulin, 1715–1716 syndromes, 1996, 1999f, 2061 Nantucket fever, 819
2
serum, 1714 MYL9, 2058, 2060 NAP-1 (neutrophil-activating peptide 1).
urine, 1714 Myocardial infarction (MI), 2294–2297 See Interleukin (IL)-8
larval, 1726 clinical features, 2295 NAP-2 (neutrophil-activating peptide 2),
minimal residual disease assessment, diagnosis, 2294–2295 1856
1716–1717 factor VIII levels and, 2226–2227 NAPc2 (nematode anticoagulant protein c2),
monocytosis and, 1097 genetic factors, 1850, 1853, 2288 2214
plasmablastic, 1742 in hemophilia, 2130 Naproxen
prognosis, 1712, 1759–1760 laboratory features, 2295 antiplatelet effects, 404, 2075
smoldering, 1708–1709, 1726, 1734f, 1761 monocytosis and, 1097 maternal ingestion of, effect on fetus and
staging, 1747–1748, 1747t, 1748t therapy, 1855, 2076, 2295–2297, 2313 newborn, 112
treatment Myoglobin, 618 Nasopharynx, history of disorders of, 5
of bone pain, 1756 Myosin, 1833t, 1842 Natural killer (NK) cell antigens, 1142,
of complications, 1756–1757 Myosin II, 1833t 1142t

Kaushansky_index_p2393-2506.indd 2469 9/21/15 3:22 PM